Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History

Cipher Pharmaceuticals Inc T.DND

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Specialty & Generic
Alternate Symbol(s):  CPHMF

Cipher Pharmaceuticals Inc is a specialty commercial stage pharmaceutical company. It focuses on development and commercialization of novel formulations of currently marketed molecules using advanced drug delivery technologies.
Price: $13.79 | Change: +$0.30 | %Change: +2.22%
Volume: 18,875 | Day High/Low: 13.79/13.60 | 52 Week High/Low: 13.66/6.75
View modes: 
0 stars

ZACKS analysis Cipher with link

We are reiterating our ‘Buy’ rating on the shares and adjusting our price target to $15 per share, or roughly 16x (industry average) our 2015 EPS estimate of $0.87 per share. http://finance.yahoo.com...read more
3 stars

Earnings Call Transcript Full

Cipher Pharmaceuticals' (CPHMF) CEO Shawn Patrick O'Brien on Q3 2014 Results - Earnings Call Transcript Oct. 29, 2014 1:06 PM ET  |  About: Cipher Pharmaceuticals, Inc. (CPHMF) ...read more
0 stars

Great job new CEO all drugs sales up

Like I said if you aren't going to maximize the profits from the drugs that are already approved what is the point in trying to bring new ones to the market.  Ciphers' new CEO is now in the process of...read more
3 stars

RE:RE:Going to Nasdaq - Now you have my attention - easily $20-$50

that is right, it is no longer a biotech but a very specialized pharma. Cash on hand and great that their other products are finally kicking in and contributing in a substantial way. They no longer...read more
3 stars

RE:Going to Nasdaq - Now you have my attention - easily $20-$50

Except that its not a biotech company... its better! Little development risk, almost no R&D cost.. what was it, 200k R&D, 2.1MM SG&A.. It just prints cash!  rate and reply
0 stars

RE:Another superb Quarter/ cash increases/Nasdaq listing

Cash balance has now increased to nearly $48 million . This will keep us in good stead when other drugs are acquired and placed into the distribution system. Should be no problem getting sponsorship...read more
0 stars

great q and other related news

Cipher Reports Financial Results for Q3 2014 1 hour 39 minutes ago Like Tweet ...read more
0 stars

Going to Nasdaq - Now you have my attention - easily $20-$50

I've been saying all along that if this was on Naz it would have at least a 40 PE which is below average for growing biotechs. 40 PE is about $43.  rate and reply
0 stars

Another superb Quarter/ cash increases/Nasdaq listing

Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Oct. 29, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and nine months...read more
5 stars

RE:RE:Wow another rocket, new high $12.84

lawsuit : out of sight, out of mind.  After the initial shock, people realizing these things are par for the course and drag on for years before any resolution. In the meantime Cipher coins money. By...read more
5 stars

RE:Wow another rocket, new high $12.84

relation to earnings not obvious.  seasonally slow summer, so likely no fireworks BNN tout supportive: http://www.bnn.ca/News/2014/10/24/Top-Picks-from-Jason-Donville-Cipher-Pharma-CGI-Group-and...read more
5 stars

Ranbaxy posts Q2 net profit of Rs 478 cr on robust sales

Drug firm Ranbaxy Laboratories today reported consolidated net profit of Rs 477.75 crore for the second quarter ended September 30, 2014-15, on account of exclusivity sales of Valsartan in US and...read more
0 stars

RE:Wow another rocket, new high $12.84

The reason for the rise was Jason Donville. It's a classic day trade after he recommends as top pick. Cipher typically reacts really well to this.  What is the status of their lawsuit? I remember...read more
0 stars

RE:Wow another rocket, new high $12.84

Just great value and growth emerging. It will continue.  rate and reply
0 stars

Wow another rocket, new high $12.84

Obviously some one knows something about the unpcoming 3rd quarter report.  rate and reply
0 stars

new 52 week high

congrats all. would seem all the good ones eventually survive the market volatility and come back nicely in sp. cheers, dave.  rate and reply
0 stars

Cipher is Jason Donville's top pick

Three top stock picks from Donville Kent’s Jason Donville Special to The Globe and Mail Published Friday, Oct. 24 2014, 7:15 PM EDT Last updated Friday, Oct. 24 2014, 7:15 PM EDT Jason Donville is...read more
0 stars

RE:Cipher still undervalued at this level PE Ratio: 9.6

PE of 16 is usually for blue chip or companies that have less then 15% growth. For a company like Cipher that has a much higher growth rate the PE can be up to 100 or even higher as with many US...read more
0 stars

RE:Cipher still undervalued at this level PE Ratio: 9.6

Not to mention, DND - EV/EBITDA is roughly 10x with RX being over 40x  rate and reply
2 stars

Cipher still undervalued at this level PE Ratio: 9.6

16 is the usual PE ratio. This baby can go much higher with more USA investment. I like this new CEO he has to keep doing what he has been doing and get more USA investors and the stock price will...read more

How to invest in private equity without writing a $1 million check.

Click here to watch the video